Live feed09:15:00·353dPRReleasevia QuantisnowLongeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)ByQuantisnow·Wall Street's wire, on your screen.LGVN· Longeveron Inc.Health Care
